📣 VC round data is live. Check it out!

3D Medicines Valuation Multiples

Discover revenue and EBITDA valuation multiples for 3D Medicines and similar public comparables like Cantargia, Dimerix, Eurofins-Cerep, Laboratorios Richmond and more.

3D Medicines Overview

About 3D Medicines

3D Medicines Inc is a commercial-stage biopharmaceutical company engaged in the research and development of oncology therapies for cancer patients, especially those who require long-term care. It develops differentiated immuno-oncology drugs, helping cancer patients live with prolonged survival time and quality of life. It generates all of its revenue from China.


Founded

2018

HQ

China

Employees

191

Financials (FY)

Revenue: $66M
EBITDA: ($24M)

EV

$52M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

3D Medicines Financials

3D Medicines reported last fiscal year revenue of $66M and negative EBITDA of ($24M).

In the same fiscal year, 3D Medicines generated $60M in gross profit, ($24M) in EBITDA losses, and had net loss of ($27M).


3D Medicines P&L

In the most recent fiscal year, 3D Medicines reported revenue of $66M and EBITDA of ($24M).

3D Medicines is unprofitable as of last fiscal year, with gross margin of 92%, EBITDA margin of (37%), and net margin of (41%).

See analyst estimates for 3D Medicines
Last FY20232024202620272028
Revenue$66M$93M$66M
Gross Profit$60M$86M$60M
Gross Margin92%92%92%
EBITDA($24M)($78M)($24M)
EBITDA Margin(37%)(83%)(37%)
EBIT Margin(18%)(66%)(18%)
Net Profit($27M)($77M)($27M)
Net Margin(41%)(83%)(41%)

Financial data powered by Morningstar, Inc.

3D Medicines Stock Performance

3D Medicines has current market cap of $94M, and enterprise value of $52M.


3D Medicines' stock price is $0.38.

3D Medicines has an EPS (earnings per share) of $-0.11.

See more trading valuation data for 3D Medicines
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$52M$94M0.0%$-0.11

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

3D Medicines Valuation Multiples

3D Medicines trades at 0.8x EV/Revenue multiple, and (2.2x) EV/EBITDA.

See NTM and 2027E valuation multiples for 3D Medicines

3D Medicines Financial Valuation Multiples

As of May 10, 2026, 3D Medicines has market cap of $94M and EV of $52M.

3D Medicines has a P/E ratio of (3.5x).

Last FY20232024202620272028
EV/Revenue0.8x0.6x0.8x
EV/EBITDA(2.2x)(0.7x)(2.2x)
EV/EBIT(4.5x)(0.8x)(4.5x)
EV/Gross Profit0.9x0.6x0.9x
P/E(3.5x)(1.2x)(3.5x)
EV/FCF(1.4x)(2.4x)(1.4x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified 3D Medicines Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

3D Medicines Margins & Growth Rates

In the most recent fiscal year, 3D Medicines reported gross margin of 92%, EBITDA margin of (37%), and net margin of (41%).

See estimated margins and future growth rates for 3D Medicines

3D Medicines Margins

Last FY2024202720282029
Gross Margin92%92%
EBITDA Margin(37%)(37%)
EBIT Margin(18%)(18%)
Net Margin(41%)(41%)
FCF Margin(57%)(57%)

3D Medicines Growth Rates

23/2426/2727/2828/29
Revenue Growth(30%)
Gross Profit Growth(30%)
EBITDA Growth(69%)
EBIT Growth(81%)
Net Profit Growth(65%)
FCF Growth70%

Data powered by FactSet, Inc. and Morningstar, Inc.

3D Medicines Operational KPIs

3D Medicines' revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.4M for the same period.

Access forward-looking KPIs for 3D Medicines
Last FY20232024202620272028
Revenue per Employee$0.3M
Opex per Employee$0.4M
S&M Expenses to Revenue53%60%53%
G&A Expenses to Revenue18%34%18%
R&D Expenses to Revenue41%67%41%
Opex to Revenue110%159%110%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

3D Medicines Competitors

3D Medicines competitors include Cantargia, Dimerix, Eurofins-Cerep, Laboratorios Richmond, Agronomics, Rein Therapeutics, aTyr Pharma, Dongkoo Bio&Pharma Co, Rani Therapeutics and Coya Therapeutics.

Most 3D Medicines public comparables operate across Biopharmaceuticals, Diagnostics & Genomics, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Cantargia2.4x3.7x5.1x21.5x
Dimerix16.2x13.1x(3.2x)(3.8x)
Eurofins-Cerep1.4x9.1x
Laboratorios Richmond2.9x10.8x
Agronomics(5.7x)(2.6x)
Rein Therapeutics(4.2x)
aTyr Pharma137.5x213.6x(0.3x)(0.4x)
Dongkoo Bio&Pharma Co0.9x3.1x

This data is available for Pro users. Sign up to see all 3D Medicines competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About 3D Medicines

When was 3D Medicines founded?3D Medicines was founded in 2018.
Where is 3D Medicines headquartered?3D Medicines is headquartered in China.
How many employees does 3D Medicines have?As of today, 3D Medicines has over 191 employees.
Is 3D Medicines publicly listed?Yes, 3D Medicines is a public company listed on HKEX.
What is the stock symbol of 3D Medicines?3D Medicines trades under 01244 ticker.
When did 3D Medicines go public?3D Medicines went public in 2022.
Who are competitors of 3D Medicines?3D Medicines main competitors include Cantargia, Dimerix, Eurofins-Cerep, Laboratorios Richmond, Agronomics, Rein Therapeutics, aTyr Pharma, Dongkoo Bio&Pharma Co, Rani Therapeutics, Coya Therapeutics.
What is the current market cap of 3D Medicines?3D Medicines' current market cap is $94M.
What is the current revenue of 3D Medicines?3D Medicines' last fiscal year revenue is $66M.
What is the current EV/Revenue multiple of 3D Medicines?Current revenue multiple of 3D Medicines is 0.8x.
Is 3D Medicines profitable?No, 3D Medicines is not profitable.
How many companies 3D Medicines has acquired to date?3D Medicines hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies 3D Medicines has invested to date?3D Medicines hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to 3D Medicines

Lists including 3D Medicines

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial